hCTLA-4(BALB/c)
Nomenclature
BALB/cAnSmoc-Ctla4em1(hCTLA4) Smoc
Cat. NO.
NM-HU-190078
Strain State
Repository Live
Gene Summary
Gene Symbol
CTLA4
Model Description
Validation Data
Figure 1. Expression of CTLA4 in the activated spleen lymphocytes of homozygous humanized CTLA4 BALB/c KI mice is detected by FACS.
Fig2. In vivo validation of homozygous BALB/c-hCTLA4 mice. The homozygous BALB/c-hCTLA4 mice were inoculated with CT26 cells, and randomly assigned to different groups (n=7) when the tumor grew to a volume of 100 mm3. A combinatorial treatment of anti-hCTLA4 antibody Yervoy and entinostat (ENT; a class I HDAC inhibitor) demonstrated a noticeable efficacy improvement compared to the same dose of single agent (A) without affecting the animal body weight (B).
Fig3. In vivo validation of homozygous BALB/c-hCTLA4 mice. The homozygous BALB/c-hCTLA4 mice were inoculated with H22 cells, and randomly assigned to different groups (n=7) when the tumor grew to a volume of 100 mm3. Treatment of anti-hCTLA4 antibody Yervoy and Teremelimumab can effectively control tumor growth in BALB/c-hCTLA4 mice (A) without affecting the animal body weight (B).
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreOur vision is to provide researchers all over the world with comprehensive, convenient and professional animal model services to facilitate a simplified and highly-efficient approach towards uncovering the mysteries of life.
Learn more
